Applied Therapeutics Inc (APLT) Stock: A Look at the Monthly Trend

In the past week, APLT stock has gone down by -1.87%, with a monthly decline of -37.62% and a quarterly plunge of -93.66%. The volatility ratio for the week is 10.09%, and the volatility levels for the last 30 days are 12.27% for Applied Therapeutics Inc The simple moving average for the past 20 days is -13.05% for APLT’s stock, with a -89.00% simple moving average for the past 200 days.

Is It Worth Investing in Applied Therapeutics Inc (NASDAQ: APLT) Right Now?

The 36-month beta value for APLT is also noteworthy at 1.87. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”

The public float for APLT is 86.61M, and at present, short sellers hold a 25.62% of that float. The average trading volume of APLT on February 05, 2025 was 6.99M shares.

APLT) stock’s latest price update

Applied Therapeutics Inc (NASDAQ: APLT) has seen a decline in its stock price by -0.39 in relation to its previous close of 0.56. However, the company has experienced a -1.87% decline in its stock price over the last five trading sessions. accessnewswire.com reported 2025-02-04 that NEW YORK, NY / ACCESS Newswire / February 4, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ:APLT) between January 3, 2024 and December 2, 2024, both dates inclusive (the “Class Period”), of the important February 18, 2025 lead plaintiff deadline. SO WHAT: If you purchased Applied Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Analysts’ Opinion of APLT

UBS, on the other hand, stated in their research note that they expect to see APLT reach a price target of $2, previously predicting the price at $13. The rating they have provided for APLT stocks is “Neutral” according to the report published on December 02nd, 2024.

RBC Capital Mkts gave a rating of “Sector Perform” to APLT, setting the target price at $4 in the report published on November 29th of the previous year.

APLT Trading at -71.17% from the 50-Day Moving Average

After a stumble in the market that brought APLT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.73% of loss for the given period.

Volatility was left at 12.27%, however, over the last 30 days, the volatility rate increased by 10.09%, as shares sank -40.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -93.73% lower at present.

During the last 5 trading sessions, APLT fell by -1.93%, which changed the moving average for the period of 200-days by -88.41% in comparison to the 20-day moving average, which settled at $0.6444. In addition, Applied Therapeutics Inc saw -34.56% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at APLT starting from Funtleyder Leslie D., who sale 13,530 shares at the price of $5.83 back on Aug 22 ’24. After this action, Funtleyder Leslie D. now owns 277,911 shares of Applied Therapeutics Inc, valued at $78,880 using the latest closing price.

Perfetti Riccardo, the Chief Medical Officer of Applied Therapeutics Inc, sale 22,681 shares at $5.83 during a trade that took place back on Aug 22 ’24, which means that Perfetti Riccardo is holding 986,853 shares at $132,230 based on the most recent closing price.

Stock Fundamentals for APLT

Current profitability levels for the company are sitting at:

  • 437.36 for the present operating margin
  • 3.79 for the gross margin

The net margin for Applied Therapeutics Inc stands at 887.73. The total capital return value is set at -12.14.

Based on Applied Therapeutics Inc (APLT), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -41.52. The debt to equity ratio resting at 0.33. The interest coverage ratio of the stock is -127.99.

Currently, EBITDA for the company is -64.53 million with net debt to EBITDA at 1.05. When we switch over and look at the enterprise to sales, we see a ratio of 150.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.06.

Conclusion

In summary, Applied Therapeutics Inc (APLT) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts